Rational, mechanism-driven discovery of novel therapeutics for infectious and inflammatory disease, directed at the proteins and pathways that sustain disease persistence and drive loss of therapeutic response. Generative models trained on comprehensive, unbiased chemical, structural and biological datasets design and optimise candidate molecules, which advance through in vitro target engagement and in vivo efficacy and pharmacokinetic validation.
Four preclinical programs across antimicrobials, oncology and dermatology.
Antimicrobials
2 programs
Oncology
1 program
Dermatology
1 program